LeAnn Norris to Neoplasms
This is a "connection" page, showing publications LeAnn Norris has written about Neoplasms.
Connection Strength
0.486
-
Systematic review of antimicrobial lock therapy for prevention of central-line-associated bloodstream infections in adult and pediatric cancer patients. Int J Antimicrob Agents. 2017 Sep; 50(3):308-317.
Score: 0.256
-
Toxicity and costs of toxicity associated with new cancer drugs: international implications. J Clin Oncol. 2014 Nov 10; 32(32):3591-2.
Score: 0.053
-
Colony-stimulating factors for febrile neutropenia. N Engl J Med. 2013 07 18; 369(3):286.
Score: 0.049
-
Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med. 2013 Mar 21; 368(12):1131-9.
Score: 0.048
-
A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012 Nov; 38(8):783-96.
Score: 0.046
-
Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist. 2019 04; 24(4):537-548.
Score: 0.018
-
Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome. J Clin Oncol. 2017 Jun 10; 35(17):1945-1951.
Score: 0.016